LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Danaher Corp
Search

Danaher Corp

Gesloten

SectorGezondheidszorg

171.94 -0.71

Strong Buy

Prijsupdate 22 mei 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

171.1

Max

172.05

Belangrijke statistieken

By Trading Economics

Inkomsten

-168M

1B

Verkoop

-887M

6B

K/W

Sectorgemiddelde

31.756

49.701

EPS

2.06

Dividendrendement

0.84

Winstmarge

17.291

Werknemers

58,000

EBITDA

-514M

1.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+34.67% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.84%

2.39%

Volgende Winsten

21 jul 2026

Volgende dividenddatum

31 jul 2026

Volgende Ex Dividend datum

26 jun 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-22B

116B

Vorige openingsprijs

172.65

Vorige sluitingsprijs

171.94

Nieuwssentiment

By Acuity

56%

44%

283 / 345 Rangschikking in Healthcare

Danaher Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 apr 2026, 11:36 UTC

Winsten

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

DJ

Lezen

21 apr 2026, 11:00 UTC

Winsten

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

DJ

Lezen

21 apr 2026, 10:06 UTC

Winsten

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

DJ

Lezen

21 apr 2026, 10:05 UTC

Winsten

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

DJ

Lezen

21 apr 2026, 10:05 UTC

Winsten

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

DJ

Lezen

21 apr 2026, 10:05 UTC

Winsten

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

DJ

Lezen

21 apr 2026, 10:04 UTC

Winsten

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

DJ

Lezen

21 apr 2026, 10:04 UTC

Winsten

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

DJ

Lezen

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Cont Ops EPS $1.45 >DHR

DJ

Lezen

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Adj EPS $2.06 >DHR

DJ

Lezen

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Sales $5.95B >DHR

DJ

Lezen

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q EPS $1.45 >DHR

DJ

Lezen

21 apr 2026, 10:00 UTC

Winsten

Danaher 1Q Net $1.03B >DHR

DJ

Lezen

17 apr 2026, 19:15 UTC

Marktinformatie

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

DJ

Lezen

17 apr 2026, 19:07 UTC

Marktinformatie

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

DJ

Lezen

17 feb 2026, 20:06 UTC

Acquisities, Fusies, Overnames

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

DJ

Lezen

17 feb 2026, 15:14 UTC

Acquisities, Fusies, Overnames

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

DJ

Lezen

17 feb 2026, 14:39 UTC

Acquisities, Fusies, Overnames

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

DJ

Lezen

17 feb 2026, 13:30 UTC

Acquisities, Fusies, Overnames

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

DJ

Lezen

17 feb 2026, 13:15 UTC

Acquisities, Fusies, Overnames

Danaher Strikes $10 Billion Deal for Masimo -- Update

DJ

Lezen

17 feb 2026, 13:03 UTC

Acquisities, Fusies, Overnames

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

DJ

Lezen

17 feb 2026, 13:03 UTC

Acquisities, Fusies, Overnames

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

DJ

Lezen

17 feb 2026, 13:02 UTC

Acquisities, Fusies, Overnames

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

DJ

Lezen

17 feb 2026, 13:02 UTC

Acquisities, Fusies, Overnames

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

DJ

Lezen

17 feb 2026, 13:02 UTC

Acquisities, Fusies, Overnames

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

DJ

Lezen

17 feb 2026, 13:01 UTC

Acquisities, Fusies, Overnames

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

DJ

Lezen

17 feb 2026, 13:00 UTC

Acquisities, Fusies, Overnames

Danaher to Buy Masimo for $180/Share >DHR MASI

DJ

Lezen

17 feb 2026, 13:00 UTC

Acquisities, Fusies, Overnames

Danaher To Acquire Masimo Corporation >DHR MASI

DJ

Lezen

17 feb 2026, 11:09 UTC

Acquisities, Fusies, Overnames

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

DJ

Lezen

17 feb 2026, 11:09 UTC

Acquisities, Fusies, Overnames

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

DJ

Lezen

Peer Vergelijking

Prijswijziging

Danaher Corp Prognose

Koersdoel

By TipRanks

34.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 231.63 USD  34.67%

Hoogste 270 USD

Laagste 184.04 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Danaher Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

15

Buy

2

Hold

0

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Danaher Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

283 / 345 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,066.82

↑ +2.48%

JNJ

Johnson and Johnson

234.57

↑ +1.33%

ABBV

AbbVie Inc

216.12

↑ +0.45%

UNH

UnitedHealth Group Inc

388.17

↑ +1.5%

AZN

AstraZeneca PLC

187.25

↓-1.32%
help-icon Live chat